about
The effects of proteasome inhibitors on bone remodeling in multiple myeloma.A virtual approach to evaluate therapies for management of multiple myeloma induced bone diseaseMGUS to myeloma: a mysterious gammopathy of underexplored significance.Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.An Evidence-Based Approach to Myeloma Bone Disease.Minimally Invasive Surgical Techniques for Management of Painful Metastatic and Primary Spinal Tumors.Development of nanomaterials for bone-targeted drug delivery.IL-7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen-activated protein kinase pathway.Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.Impaired extracellular matrix structure resulting from malnutrition in ovariectomized mature rats.Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.Bone Marrow Micro-Environment in Normal and Deranged Hematopoiesis: Opportunities for Regenerative Medicine and Therapies.Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.Bone-targeted agents in multiple myeloma.Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone diseaseLIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic RegimensAtypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma
P2860
Q33918020-48D8BF7F-7249-47F6-96CC-B52E013039C7Q37185494-C391E442-5742-4055-9499-89DC31146840Q38979865-8121C9E9-0D15-40B9-B52C-238EE4D5D1F2Q39134205-2BAD9EB3-11FF-4DDD-BB2B-72B411FED591Q39153978-463857C8-CAD2-49B6-B93A-09F92A1035ACQ39156406-B499610F-8C96-4987-A9F6-5AABB9527E2DQ39294078-749CCCB5-ECAE-4F69-B341-7F6BFED3FB48Q39436450-7E483D82-11EB-4FCD-8E61-ED3B4A1E0659Q39595554-DAB7E28D-7F66-4CE3-BEA6-77F95E8F58C1Q40696173-B73B9E1B-FD36-4CE8-945B-226012244355Q41548439-F029A533-C327-4650-88A6-01866496DAB8Q45219853-C5451614-A22B-4CB3-805C-2A3B598DF90FQ47141750-179A3ED0-1CA2-40CE-8C77-BE558C53ACF4Q49562964-E35C0302-7B69-46B7-AF2B-C0032FDA3F2FQ54956715-4CD4A445-956B-450D-869F-3C7E325D6D6DQ55395268-49F7CDB6-5A3C-4DF2-82C4-336DC8E3FEC7Q57172251-27BDBBFC-EAFB-46C4-A396-5DE06016FD8EQ58572512-8C62302D-5FA7-4FF1-852F-4FE05B950455Q58774460-1AD6C6B9-3FA2-4340-A62D-3C40AAABC1B8
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Myeloma bone disease: Pathophysiology and management.
@en
Myeloma bone disease: Pathophysiology and management.
@nl
type
label
Myeloma bone disease: Pathophysiology and management.
@en
Myeloma bone disease: Pathophysiology and management.
@nl
prefLabel
Myeloma bone disease: Pathophysiology and management.
@en
Myeloma bone disease: Pathophysiology and management.
@nl
P2860
P1476
Myeloma bone disease: Pathophysiology and management.
@en
P2093
G David Roodman
Rebecca Silbermann
P2860
P356
10.1016/J.JBO.2013.04.001
P407
P577
2013-04-18T00:00:00Z